Literature DB >> 22644539

A possible pathophysiological role of tyrosine hydroxylase in Parkinson's disease suggested by postmortem brain biochemistry: a contribution for the special 70th birthday symposium in honor of Prof. Peter Riederer.

Akira Nakashima1, Akira Ota, Yoko S Kaneko, Keiji Mori, Hiroshi Nagasaki, Toshiharu Nagatsu.   

Abstract

Postmortem brain biochemistry has revealed that the main symptom of movement disorder in Parkinson's disease (PD) is caused by a deficiency in dopamine (DA) at the nerve terminals of degenerating nigro-striatal DA neurons in the striatum. Since tyrosine hydroxylase (TH) is the rate-limiting enzyme for the biosynthesis of DA, TH may play an important role in the disease process of PD. DA regulated by TH activity is thought to interact with α-synuclein protein, which results in intracellular aggregates called Lewy bodies and causes apoptotic cell death during the aging process. Human TH has several isoforms produced by alternative mRNA splicing, which may affect activation by phosphorylation of serine residues in the N-terminus of TH. The activity and protein level of TH are decreased to cause DA deficiency in the striatum in PD. However, the homo-specific activity (activity/enzyme protein) of TH is increased. This increase in TH homo-specific activity suggests activation by increased phosphorylation at the N-terminus of the TH protein for a compensatory increase in DA synthesis. We recently found that phosphorylation of the N-terminal portion of TH triggers proteasomal degradation of the enzyme to increase TH turnover. We propose a hypothesis that this compensatory activation of TH by phosphorylation in the remaining DA neurons may contribute to a further decrease in TH protein and activity in DA neurons in PD, causing a vicious circle of decreasing TH activity, protein level and DA contents. Furthermore, increased TH homo-specific activity leading to an increase in DA may cause toxic reactive oxygen species in the neurons to promote neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22644539     DOI: 10.1007/s00702-012-0828-5

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  48 in total

Review 1.  Autosomal recessive parkinsonism.

Authors:  Vincenzo Bonifati
Journal:  Parkinsonism Relat Disord       Date:  2012-01       Impact factor: 4.891

2.  Proteasomal degradation of tyrosine hydroxylase and neurodegeneration.

Authors:  Akira Nakashima
Journal:  J Neurochem       Date:  2012-01       Impact factor: 5.372

3.  Sandwich enzyme immunoassay of dopamine-?-hydroxylase in cerebrospinal fluid from control and parkinsonian patients.

Authors:  M Mogi; M Harada; K Kojima; H Inagaki; T Kondo; H Narabayashi; T Arai; R Teradaira; K Fujita; K Kiuchi; T Nagatsu
Journal:  Neurochem Int       Date:  1988       Impact factor: 3.921

4.  gp130 cytokines stimulate proteasomal degradation of tyrosine hydroxylase via extracellular signal regulated kinases 1 and 2.

Authors:  Xiao Shi; Beth A Habecker
Journal:  J Neurochem       Date:  2011-11-11       Impact factor: 5.372

Review 5.  Milestones in PD genetics.

Authors:  Thomas Gasser; John Hardy; Yoshikuni Mizuno
Journal:  Mov Disord       Date:  2011-05       Impact factor: 10.338

6.  Isolation and characterization of the human tyrosine hydroxylase gene: identification of 5' alternative splice sites responsible for multiple mRNAs.

Authors:  K L O'Malley; M J Anhalt; B M Martin; J R Kelsoe; S L Winfield; E I Ginns
Journal:  Biochemistry       Date:  1987-11-03       Impact factor: 3.162

7.  Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease.

Authors:  Jin Xu; Shyan-Yuan Kao; Frank J S Lee; Weihong Song; Lee-Way Jin; Bruce A Yankner
Journal:  Nat Med       Date:  2002-06       Impact factor: 53.440

8.  Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells.

Authors:  Xiangmin Peng; Xiangmin M Peng; Roya Tehranian; Paula Dietrich; Leonidas Stefanis; Ruth G Perez
Journal:  J Cell Sci       Date:  2005-07-19       Impact factor: 5.285

9.  Angiotensin-(1-7) through AT receptors mediates tyrosine hydroxylase degradation via the ubiquitin-proteasome pathway.

Authors:  María A Lopez Verrilli; Carlos J Pirola; Mariano M Pascual; Fernando P Dominici; Daniel Turyn; Mariela M Gironacci
Journal:  J Neurochem       Date:  2009-01-22       Impact factor: 5.372

Review 10.  α-Synuclein and dopamine at the crossroads of Parkinson's disease.

Authors:  Lara Lourenço Venda; Stephanie J Cragg; Vladimir L Buchman; Richard Wade-Martins
Journal:  Trends Neurosci       Date:  2010-10-18       Impact factor: 13.837

View more
  14 in total

1.  ser31 Tyrosine hydroxylase phosphorylation parallels differences in dopamine recovery in nigrostriatal pathway following 6-OHDA lesion.

Authors:  Michael F Salvatore
Journal:  J Neurochem       Date:  2014-01-27       Impact factor: 5.372

2.  Acrolein-mediated alpha-synuclein pathology involvement in the early post-injury pathogenesis of mild blast-induced Parkinsonian neurodegeneration.

Authors:  Glen Acosta; Nicholas Race; Seth Herr; Joseph Fernandez; Jonathan Tang; Edmond Rogers; Riyi Shi
Journal:  Mol Cell Neurosci       Date:  2019-06-12       Impact factor: 4.314

Review 3.  Prolyl oligopeptidase and dipeptidyl peptidase II/dipeptidyl peptidase IV ratio in the cerebrospinal fluid in Parkinson's disease: historical overview and future prospects.

Authors:  Toshiharu Nagatsu
Journal:  J Neural Transm (Vienna)       Date:  2016-08-08       Impact factor: 3.575

4.  Identification of Critical Genes and miRNAs Associated with the Development of Parkinson's Disease.

Authors:  Jia Li; Yajuan Sun; Jiajun Chen
Journal:  J Mol Neurosci       Date:  2018-08-06       Impact factor: 3.444

Review 5.  Human tyrosine hydroxylase in Parkinson's disease and in related disorders.

Authors:  Toshiharu Nagatsu; Akira Nakashima; Hiroshi Ichinose; Kazuto Kobayashi
Journal:  J Neural Transm (Vienna)       Date:  2018-07-11       Impact factor: 3.575

6.  Valproic Acid Neuroprotection in the 6-OHDA Model of Parkinson's Disease Is Possibly Related to Its Anti-Inflammatory and HDAC Inhibitory Properties.

Authors:  José Christian Machado Ximenes; Kelly Rose Tavares Neves; Luzia Kalyne A M Leal; Marta Regina Santos do Carmo; Gerly Anne de Castro Brito; Maria da Graça Naffah-Mazzacoratti; Ésper Abrão Cavalheiro; Glauce Socorro de Barros Viana
Journal:  J Neurodegener Dis       Date:  2015-02-19

7.  Functional studies of tyrosine hydroxylase missense variants reveal distinct patterns of molecular defects in Dopa-responsive dystonia.

Authors:  Agnete Fossbakk; Rune Kleppe; Per M Knappskog; Aurora Martinez; Jan Haavik
Journal:  Hum Mutat       Date:  2014-06-03       Impact factor: 4.878

8.  Tyrosine Hydroxylase Binding to Phospholipid Membranes Prompts Its Amyloid Aggregation and Compromises Bilayer Integrity.

Authors:  Anne Baumann; Ana Jorge-Finnigan; Kunwar Jung-Kc; Alexander Sauter; Istvan Horvath; Ludmilla A Morozova-Roche; Aurora Martinez
Journal:  Sci Rep       Date:  2016-12-22       Impact factor: 4.379

9.  Bioactive constituents from cinnamon, hemp seed and polygonum cuspidatum protect against H2O2 but not rotenone toxicity in a cellular model of Parkinson's disease.

Authors:  Suzanne A Maiolo; Peihong Fan; Larisa Bobrovskaya
Journal:  J Tradit Complement Med       Date:  2018-04-30

10.  The quaternary structure of human tyrosine hydroxylase: effects of dystonia-associated missense variants on oligomeric state and enzyme activity.

Authors:  Peter D Szigetvari; Gopinath Muruganandam; Juha P Kallio; Erik I Hallin; Agnete Fossbakk; Remy Loris; Inari Kursula; Lisbeth B Møller; Per M Knappskog; Petri Kursula; Jan Haavik
Journal:  J Neurochem       Date:  2018-12-09       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.